Maxime Dely: Helping Patients Live More Freely with Sickle Cell Disease
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Sickle cell disease: an invisible illness with very real consequences
Often invisible from the outside, sickle cell disease remains one of the most common genetic disorders in France, affecting around 30.000 people. Behind this apparent invisibility lies a chronic condition that can deeply impact daily life.
This disease is caused by a genetic abnormality of hemoglobin, leading to the deformation of some red blood cells. Less flexible, these cells struggle to circulate through small blood vessels, causing pain crises, chronic anemia, and sometimes severe organ complications.
Treatment options are diverse: symptomatic care, prevention of complications, transfusions, and today, the development of gene therapies offering real hope for curative treatment.
Among the most effective approaches, red blood exchange by apheresis makes it possible to remove altered red blood cells and replace them with healthy donor red blood cells. This technique reduces blood viscosity, limits iron overload, and helps space out treatment sessions.
Beyond every protocol, there is one simple goal: helping patients live more freely.”
Other posts featuring Maxime Dely on Hemostasis Today.
-
Jul 6, 2026, 13:37Rachad Zayat: Acute PE Study Finds USAT Associated With Better In-Hospital Outcomes
-
Jul 6, 2026, 13:28Inna Vilshanivska: Sharing Ukraine’s Experience in Blood Donor Retention at the ISBT 2026
-
Jul 6, 2026, 13:10Arun V. J.: Did You Know A Glass Of Water is The Best Way To Retain A Blood Donor?
-
Jul 6, 2026, 13:10Javed Anees: The Hidden Power of Biotin in Modern Medicine
-
Jul 6, 2026, 12:46Saneha Anjum Shaikh: Red Cell Aliquoting – Precision in Transfusion Medicine
-
Jul 6, 2026, 12:43Jennifer Dumont: WFH 2026 Congress Highlights – Expert Insights on Hemophilia Care
-
Jul 6, 2026, 12:39Muhammad Hamza: Can Hemolysis Affect Laboratory Results?
-
Jul 6, 2026, 12:32Syed A. Rizvi: Natural Blood Thinners – What Does the Science Really Say
-
Jul 6, 2026, 12:27Abdul Mannan: Perioperative Bridging of Warfarin Patients Is a Risk-Based Decision